The estimated Net Worth of Peter A. Thompson is at least $60.3 Million dollars as of 27 December 2023. Peter Thompson owns over 1,546,347 units of Corvus Pharmaceuticals Inc stock worth over $1,207,920 and over the last 9 years he sold CRVS stock worth over $58,732,608. In addition, he makes $342,177 as Independent Director at Corvus Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Peter Thompson CRVS stock SEC Form 4 insiders trading
Peter has made over 26 trades of the Corvus Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,546,347 units of CRVS stock worth $28,669,273 on 27 December 2023.
The largest trade he's ever made was buying 1,712,400 units of Corvus Pharmaceuticals Inc stock on 20 May 2016 worth over $17,843,208. On average, Peter trades about 266,473 units every 46 days since 2016. As of 27 December 2023 he still owns at least 264,315 units of Corvus Pharmaceuticals Inc stock.
You can see the complete history of Peter Thompson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Thompson biography
Dr. Peter Thompson M.D. serves as Independent Director of the Company. Dr. Thompson currently serves as a Private Equity Partner for OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as Venture Partner since joining in September 2010. Dr. Thompson has served as a director of Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014. Dr. Thompson currently serves on the boards of directors of several private companies. He is a board-certified internist and oncologist and has served as Affiliate Professor of Neurosurgery at the University of Washington since January 2010. Dr. Thompson co-founded and served as the Chief Executive Officer of Trubion Pharmaceuticals, Inc., a biopharmaceutical company, from 2002 to 2009. He was a medical staff fellow at the National Cancer Institute from 1985 to 1992. Dr. Thompson holds a B.Sc. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
What is the salary of Peter Thompson?
As the Independent Director of Corvus Pharmaceuticals Inc, the total compensation of Peter Thompson at Corvus Pharmaceuticals Inc is $342,177. There are 7 executives at Corvus Pharmaceuticals Inc getting paid more, with Daniel Hunt having the highest compensation of $1,554,080.
How old is Peter Thompson?
Peter Thompson is 60, he's been the Independent Director of Corvus Pharmaceuticals Inc since 2014. There are 8 older and 9 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.
What's Peter Thompson's mailing address?
Peter's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.
Insiders trading at Corvus Pharmaceuticals Inc
Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams, and Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.
What does Corvus Pharmaceuticals Inc do?
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
What does Corvus Pharmaceuticals Inc's logo look like?
Complete history of Peter Thompson stock trades at Adaptimmune Therapeutics Plc, Corvus Pharmaceuticals Inc, Alpine Immune Sciences Inc, Prevail Therapeutics Inc, Pmv Pharmaceuticals Inc, and Silverback Therapeutics
Corvus Pharmaceuticals Inc executives and stock owners
Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Daniel Hunt,
Senior Vice President, Chief Business Officer -
Mehrdad Mobasher,
Vice President, Chief Medical Officer -
Richard Miller,
Chairman of the Board, President, Chief Executive Officer -
Leiv Lea,
Chief Financial Officer -
Dr. Mehrdad Mobasher M.D., M.P.H.,
Sr. VP & Chief Medical Officer -
Leiv Lea,
Chief Financial Officer -
Steve Krognes,
Independent Director -
Peter Thompson,
Independent Director -
Elisha Gould,
Independent Director -
Dr. Richard A. Miller M.D.,
Co-Founder, Pres, CEO & Chairman -
Scott Morrison,
Independent Director -
Dr. Peter A. Thompson FACP, M.D.,
Co-Founder & Independent Director -
Linda Grais,
Independent Director -
Ian Clark,
Independent Director -
Edith Mitchell,
Director -
Erik Verner,
Vice President of Chemistry Research -
William Jones,
Senior Vice President of Pharmaceutical Development -
Dr. James T. Rosenbaum M.D.,
Sr. VP of Research -
Dr. Erik J. Verner Ph.D.,
Co-Founder -
Stephen Willingham,
Sr. Scientist -
Alan C. Mendelson Esq.,
Sec. -
Dr. Long Kwei Ph.D.,
Sr. VP of Biometrics -
Dr. William Benton Jones,
Sr. VP of Pharmaceutical Devel. -
Debra Horen SPHR,
VP of HR -
Street Partners Llc Adams,
10% owner -
Advisors Llc Orbi Med Capit...,
-
Jason V Coloma,
SVP, Chief Business Officer -
Holdings A/S Novo,
10% owner -
Advisors Llc Orbimed,
Director -
Terry P Gould,
-
Joseph J Buggy,
EVP, Discovery Research -
Advisors Llc Orbi Med Capit...,
-
Capital, Llc Eco R1,
10% owner -
Jeffrey Arcara,
Chief Business Officer